Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $38.91.

DNLI has been the topic of several recent analyst reports. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target on the stock. Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. HC Wainwright decreased their price target on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th.

Denali Therapeutics Trading Up 0.8 %

DNLI opened at $21.67 on Friday. The stock has a market cap of $3.12 billion, a PE ratio of -7.85 and a beta of 1.39. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The stock’s 50 day simple moving average is $23.32 and its 200-day simple moving average is $24.74.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the company posted ($0.72) earnings per share. Equities analysts forecast that Denali Therapeutics will post -2.73 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Alexander O. Schuth sold 15,558 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the transaction, the insider now owns 178,066 shares of the company’s stock, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,518 shares of company stock valued at $1,469,382 over the last 90 days. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently made changes to their positions in DNLI. FMR LLC increased its holdings in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Denali Therapeutics in the second quarter valued at about $24,454,000. Wellington Management Group LLP increased its holdings in Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the last quarter. Finally, Integral Health Asset Management LLC bought a new stake in Denali Therapeutics in the second quarter valued at about $7,546,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.